Bibliography
- Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005;4:298-306
- Kalluri H, Banga AK. Transdermal delivery of proteins. AAPS PharmSciTech 2011;12:431-41
- Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 2006;11:905-10
- Scheuch G, Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol 2007;58:615-25
- Tranchand B. Guide pratique de pharmacocinétique clinique en oncologie, Editions Frison-Roche, 1997
- Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84
- Wilson AC, Meethal SV, Bowen RL, Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Drug Eval 2007;16:1851-63
- Sanofi-Aventis, ELIGARD 7,5 mg product information. 2009
- Chodak G. A critical review of maximal androgen blockade for advanced prostate cancer. Rev Urol 2004;6:18-23
- Kostanski JW, Dani BA, Schrier B, Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats. Pharm Res 2000;17:445-50
- Klijn JG, Blamey RW, Boccardo F, Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53
- Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998;4:527-34
- Emons G, Ortmann O, Schulz KD, Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab 1997;8:355-62
- Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002;109:E30
- Covens A, Thomas G, Shaw P, A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 1997;64:126-9
- Kavanagh JJ, Roberts W, Townsend P, Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989;7:115-18
- Webber KM, Casadesus G, Bowen RL, Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 2007;7:300-3
- Webber KM, Perry G, Smith MA, The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res 2007;5:177-83
- Stevenson CL, Leonard JJ, Hall SC. Effect of peptide concentration and temperature on leuprolide stability in dimethyl sulfoxide. Int J Pharm 1999;191:115-29
- Wright JC, Tao Leonard S, Stevenson CL, An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Control Release 2001;75:1-10
- Viadur. Available from: http://www.pharma.bayer.com 2010
- MicroCHIPS, Inc. Available from: http://www.mchips.com 2010
- Li Y, Shawgo RS, Tyler B, In vivo release from a drug delivery MEMS device. J Control Release 2004;100:211-19
- Maloney JM, Uhland SA, Polito BF, Electrothermally activated microchips for implantable drug delivery and biosensing. J Control Release 2005;109:244-55
- Prescott JH, Lipka S, Baldwin S, Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotechnol 2006;24:437-8
- Prescott JH, Krieger TJ, Lipka S, Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multi-reservoir array. Pharm Res 2007;24:1252-61
- Luan X, Bodmeier R. Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly(lactide-co-glycolide) microparticles. Eur J Pharm Biopharm 2006;63:205-14
- Ravivarapu HB, Burton K, DeLuca PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm 2000;50:263-70
- Packhaeuser CB, Schnieders J, Oster CG, In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004;58:445-55
- Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release 2002;80:9-28
- Singh S, Singh J. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits. Int J Pharm 2007;328:42-8
- QLT, Inc. Available from: http://www.qltinc.com 2010
- Luan X, Bodmeier R. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters. Eur J Pharm Sci 2006;27:143-9
- Kranz H, Brazeau GA, Napaporn J, Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm 2001;212:11-18
- Dong WY, Korber M, Lopez Esguerra V, Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. J Control Release 2006;115:158-67
- Pacira Pharmaceuticals. Available from: http://www.pacira.com 2010
- Ye Q, Asherman J, Stevenson M, DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. J Control Release 2000;64:155-66
- Slager J, Domb AJ. Hetero-stereocomplexes of D-poly(lactic acid) and the LHRH analogue leuprolide. Application in controlled release. Eur J Pharm Biopharm 2004;58:461-9
- Arulsudar N, Subramanian N, Mishra P, Preparation, characterization, and biodistribution study of technetium-99 m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. AAPS PharmSci 2004;6:E5
- Singh P, Maibach HI. Iontophoresis: an alternative to the use of carriers in cutaneous drug delivery. Adv Drug Deliv Rev 1996;18:379-94
- Merino V, Kalia YN, Guy RH. Transdermal therapy and diagnosis by iontophoresis. Trends Biotechnol 1997;15:288-90
- Schuetz YB, Carrupt PA, Naik A, Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis. Eur J Pharm Sci 2006;29:53-9
- Kochhar C, Imanidis G. In vitro transdermal iontophoretic delivery of leuprolide under constant current application. J Control Release 2004;98:25-35
- Kochhar C, Imanidis G. In vitro transdermal iontophoretic delivery of leuprolide-mechanisms under constant voltage application. J Pharm Sci 2003;92:84-96
- Delgado-Charro MB, Guy RH. Iontophoretic delivery of nafarelin across the skin. Int J Pharm 1995;117:165-72
- Meyer BR, Kreis W, Eschbach J, Transdermal versus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect. Clin Pharmacol Ther 1990;48:340-5
- Zheng Y, FuLu MY, Qiu Y, Enzymatic degradation of leuprolide in rat intestinal mucosal homogenates. Pharm Dev Technol 1999;4:539-44
- Zheng Y, Qiu Y, Lu MF, Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. Int J Pharm 1999;185:83-92
- Zheng JY, Fulu MY. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion. Int J Pharm 2006;307:209-15
- Guo J, Ping Q, Jiang G, Chitosan-coated liposomes: characterization and interaction with leuprolide. Int J Pharm 2003;260:167-73
- Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev 2001;47:83-97
- Iqbal J, Shahnaz G, Perera G, Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. Eur J Pharm Biopharm 2012;80:95-102
- Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev 2005;57:1569-82
- Guo J, Ping Q, Jiang G, Transport of leuprolide across rat intestine, rabbit intestine and Caco-2 cell monolayer. Int J Pharm 2004;278:415-22
- Iqbal J, Vigl C, Moser G, Development and in vivo evaluation of a new oral nanoparticulate dosage form for leuprolide based on polyacrylic acid. Drug Deliv 2011;18:432-40
- Soligenix. Available from: http://www.soligenix.com 2010
- Teutonico D, Ponchel G. Patches for improving gastrointestinal absorption: an overview. Drug Discov Today 2011;16:991-7
- Teutonico D, Montanari S, Ponchel G. Concentration and surface of absorption: concepts and applications to gastrointestinal patches delivery. Int J Pharm 2011;413:87-92
- Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech 2005;6:E482-6
- Adjei A, Hui J, Finley R, Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and preclinical issues. Int J Pharm 1994;107:57-66
- Adjei A, Sundberg D, Miller J, Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res 1992;9:244-9
- Suzuki Y, Makino Y. Mucosal drug delivery using cellulose derivatives as a functional polymer. J Control Release 1999;62:101-7
- Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004;26:137-42
- Alcock R, Blair JA, O'Mahony DJ, Modifying the release of leuprolide from spray dried OED microparticles. J Control Release 2002;82:429-40
- Qiu Y, Johnson HW, Reiland TL, Sublingual absorption of leuprolide: comparison between human and animal models. Int J Pharm 1999;179:27-36
- Lupron. Available from: http://www.lupron.com 2010
- Eligard. Available from: http://www.eligard.com 2010
- Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 2007;13:241-5
- Agarwal N, Fletcher D, Ward J. Obesity and treatment of prostate cancer: what is the right dose of lupron depot? Clin Cancer Res 2007;13:4027
- Heidenreich A, Aus G, Bolla M, EAU guidelines on prostate cancer. European Urology 2008;53(1):68-80
- Petrus M, Vigouroux A, Dumas C, L'allergie a la triptoreline: revue et commentaires a propos d'un cas pediatrique. Revue Francaise d'Allergologie Et d'Immunologie Clinique 2007;47:89-91
- Raj SG, Karadsheh AJ, Guillot RJ, Case report: systemic hypersensitivity reaction to goserelin acetate. Am J Med Sci 1996;312:187-90
- Lam C, Tjon J, Hamilton J, Recurrent anaphylaxis associated with gonadotropin-releasing hormone analogs: case report and review of the literature. Pharmacotherapy 2006;26:1811-15
- Taylor JD. Anaphylactic reaction to LHRH analogue, leuprorelin. Med J Aust 1994;161:455
- TAP Pharmaceuticals, Lupron depot 7.5 mg prescribing infrmations. 2010
- Lucrin. Available from: http://www.lucrin.nl 2010
- Takeda. Available from: http://www.takeda.com 2010
- Abbott. Available from: http://www.abbott.com 2010
- Eriochem. Available from: http://www.eriochem.com 2010
- Sanofi-Aventis, Suprefact (Buserelin acetate) - prescribing informations. 2010
- AstraZaneca, Zoladex (goserelin) product prescribing informations. 2010
- AstraZeneca. Available from: http://www.astrazaneca.com 2010
- Endo Pharmaceuticals, Vantas (histrelin implant) prescribing informations. 2010
- Endo Pharmaceuticals. Available from: http://www.endo.com 2010
- Pfizer, Synarel (nafarelin acetate) nasal solution prescribing information. 2005
- Pfizer. Available from: http://www.pfizer.com 2010
- Ipsen, Diphereline S.R. 11.25 mg prescribing informations. 2004
- Ferring Pharmaceuticals. Available from: http://www.ferring.com 2010
- Watson. Available from: http://www.watson.com 2010
- Sanofi Aventis. Available from: Press release 26 Jenuary 2005 2010
- Consumer Medicine Information. Available from: http://www.betterhealth.vic.gov.au/ Lucrin Injection 2010
- Enantone monograph. Available from: http://www.mims.com/; (n.d.)
- Takeda Pharmaceuticals, Enantone 3.75/2 ml patient information leaflet. 2008
- Bayer HealthCare Pharmaceuticals, Viadur (leuprolide acetate implant) prescribing informations. 2005
- Kahn A, Gisselbrecht S. Histoire de la therapie ciblee en cancerologie, Amgen Oncologie - John Libbey Eurotext. 2007.